Solventum Stock Plummets -7.2% With 5-Day Losing Streak
Solventum (SOLV) – a healthcare company developing and commercializing critical patient solutions – hit a 5-day losing streak, with cumulative losses over this period amounting to -7.2%. The company’s market cap has crashed by about $1.0 Bil over the last 5 days and currently stands at $13 Bil.
Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
But here is the interesting part. You are reading about this -7.2% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Micron Technology Stock Surged On A Shortage The Company Had Already Described
- The Real Upside Case For Mastercard Stock Is In The Plumbing
- Tesla Stock’s Deepest Fall Was Worse Than Its Worst Market Crash
- Karman Stock: 7 Straight Green Days, Up 28%
- 5 Green Days In A Row: Unity Software Stock Is Up 36%
- A 7-Day Winning Streak Has Kratos Defense & Security Solutions Stock Up 38%
The following table summarizes the return for SOLV stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SOLV | S&P 500 |
|---|---|---|
| 1D | -0.4% | -0.6% |
| 5D (Current Streak) | -7.2% | 1.7% |
| 1M (21D) | 3.1% | 1.4% |
| 3M (63D) | 11.5% | 11.8% |
| YTD 2026 | -3.4% | 9.7% |
| 2025 | 20.0% | 16.4% |
| 2024 | 23.3% | |
| 2023 | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 119 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 35 | 16 |
| 4D | 74 | 3 |
| 5D | 1 | 2 |
| 6D | 9 | 0 |
| 7D or more | 0 | 2 |
| Total >=3 D | 119 | 23 |
Key Financials for Solventum (SOLV)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $8.3 Bil | $8.3 Bil |
| Operating Income | $1.0 Bil | $632.0 Mil |
| Net Income | $479.0 Mil | $1.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $2.0 Bil | $2.0 Bil |
| Operating Income | $93.0 Mil | $79.0 Mil |
| Net Income | $63.0 Mil | $13.0 Mil |
The losing streak SOLV stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.